Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy

BACKGROUND: Ovarian cancer is the leading cause of death in women with gynecological malignancy worldwide. Despite multiple new approaches to treatment, relapse remains almost inevitable in patients with advanced disease. The poor outcome of advanced ovarian cancer treated with conventional therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Sui, Hongying, Shi, Caixia, Yan, Zhipeng, Li, Hucheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482371/
https://www.ncbi.nlm.nih.gov/pubmed/26124641
http://dx.doi.org/10.2147/DDDT.S82035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482371/
https://www.ncbi.nlm.nih.gov/pubmed/26124641
http://dx.doi.org/10.2147/DDDT.S82035

Ejemplares similares